Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-24

mac why would a company even need to say they’re prudently spending money. It is expected they aren’t frivolous with our money, no? why would the company need to suggest they are looking to extend spending timelines with +20m in the bank about to start a clinical trial for commercialization other than having an agenda that is impossible to read between the lines in a 1 page document.

Starting the trial “as soon as possible” is not the same as immediately after clinical trial approval in my opinion. “As soon as possible” has no timeline and is subjective.

These kinds of statements “In parallel the Company has been extensively evaluating its clinical plans for ATL1102 in DMD with the focus on deploying its existing cash reserves in the most effective manner, to reduce upfront capital requirements and extend its cash runway.” Are meaningless without having any backing information. What evaluation criteria, what is “extensively” evaluating, who has done this, what are the outcomes of this evaluation, has it changed the strategy moving forward?

Maybe explaining what options are on the table to manage spending would be good, can they undertake trials in half the sites instead?

I hope md can take a step back and think about what he would expect, as an investor, to be given enough confidence to sink his hard earned into a company. Or even giving enough confidence an institution or pharma for that matter.

not hating on you, just sharing opinions. Excited that the ball is officially rolling on EU trials but have had a knock to my confidence in it going as expected.